{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:13:30Z","timestamp":1791004410566,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00345-021-03666-w","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T02:02:47Z","timestamp":1616810567000},"page":"4037-4046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?"],"prefix":"10.1007","volume":"39","author":[{"given":"Cedric","family":"Lebacle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6321-9144","authenticated-orcid":false,"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"3666_CR1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette\u2013Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247","journal-title":"Eur Urol"},{"issue":"5","key":"3666_CR2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, Gore JL (2017) Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol 197(5):1189\u20131199","journal-title":"J Urol"},{"key":"3666_CR3","unstructured":"Administration UFD (2018) II. Development program. In: UDoHaH rie (eds) BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry, Office of Communications, Division of Drug Information, Silver Spring, pp 1\u201310"},{"key":"3666_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner SP et al (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27:155","journal-title":"Urol Oncol"},{"key":"3666_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","volume":"78","author":"R Li","year":"2020","unstructured":"Li R, Sundi D, Zhang J et al (2020) Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette\u2013Gu\u00e9rin. Eur Urol 78:387\u2013399","journal-title":"Eur Urol"},{"key":"3666_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D et al (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14:244\u2013255","journal-title":"Nat Rev Urol"},{"key":"3666_CR7","unstructured":"European Urology Guidelines. https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/. Accessed 15 Dec 2020"},{"key":"3666_CR8","first-page":"E216","volume":"110","author":"H Shirakawa","year":"2012","unstructured":"Shirakawa H, Kikuchi E, Tanaka N et al (2012) Prognostic significance of Bacillus Calmette\u2013Gu\u00e9rin failure classification in non-muscle-invasive bladder cancer. BJU Int 110:E216\u2013E221","journal-title":"BJU Int"},{"key":"3666_CR9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62\u201367","journal-title":"J Urol"},{"key":"3666_CR10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JW et al (2012) Treatment options available for Bacillus Calmette\u2013Gu\u00e9rin failure in non\u2013muscle-invasive bladder cancer. Eur Urol 62:1088\u20131096","journal-title":"Eur Urol"},{"key":"3666_CR11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high-risk superficial bladder tumors? J Urol 166:1296\u20131299","journal-title":"J Urol"},{"key":"3666_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666\u2013675","journal-title":"J Clin Oncol"},{"key":"3666_CR13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher BL et al (2008) Impact of previous Bacille Calmette\u2013Guerin failure pattern on subsequent response to Bacille Calmette\u2013Guerin plus interferon intravesical therapy. Urology 71:297","journal-title":"Urology"},{"key":"3666_CR14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","volume":"186","author":"HM Rosevear","year":"2011","unstructured":"Rosevear HM et al (2011) Factors affecting response to Bacillus Calmette\u2013Guerin plus interferon for urothelial carcinoma in situ. J Urol 186:817","journal-title":"J Urol"},{"key":"3666_CR15","first-page":"CD012112","volume":"3","author":"AR Shepherd","year":"2017","unstructured":"Shepherd AR, Shepherd E, Brook NR (2017) Intravesical BCG with IFN-alpha versus intravesical BCG for treating NMIBC. Cochrane Database Syst Rev 3:CD012112","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3666_CR16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","volume":"193","author":"A Morales","year":"2015","unstructured":"Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat A (2015) Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with Bacillus Calmette\u2013Gu\u00e9rin. J Urol 193(4):1135\u20131143","journal-title":"J Urol"},{"issue":"1","key":"3666_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","volume":"3","author":"R Li","year":"2017","unstructured":"Li R, Amrhein J, Cohen Z, Champagne M, Kamat A (2017) Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer 3(1):65\u201371","journal-title":"Bladder Cancer"},{"key":"3666_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","volume":"143","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"1990","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA et al (1990) Bacillus Calmette\u2013Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143:502\u2013506","journal-title":"J Urol"},{"key":"3666_CR19","first-page":"CD009294","volume":"1","author":"G Jones","year":"2012","unstructured":"Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M (2012) Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev 1:CD009294","journal-title":"Cochrane Database Syst Rev"},{"key":"3666_CR20","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Perdon\u00e0 S, Damiano R, Faiella A, Cantiello F, Pignata S, Ascierto P, Simeone E, De Sio M, Autorino R (2010) Gemcitabine versus bacille Calmette\u2013Guerin after initial Bacille Calmette\u2013Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116:1893","journal-title":"Cancer"},{"key":"3666_CR21","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","volume":"24","author":"G Dalbagni","year":"2006","unstructured":"Dalbagni G, Russo P, Bochner B, Ben-Pora L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D (2006) Phase II trial of intravesical gemcitabine in Bacille Calmette\u2013Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729","journal-title":"J Clin Oncol"},{"issue":"4","key":"3666_CR22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"EC Skinner","year":"2013","unstructured":"Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz H-J, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM (2013) SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette\u2013Gu\u00e9rin. J Urol 190(4):1200\u20131204","journal-title":"J Urol"},{"issue":"3","key":"3666_CR23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","volume":"27","author":"LJ Barlow","year":"2009","unstructured":"Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27(3):331\u2013335","journal-title":"World J Urol"},{"issue":"3","key":"3666_CR24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"LJ Barlow","year":"2013","unstructured":"Barlow LJ, McKiernan JM, Benson MC (2013) Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin Therapy. J Urol 189(3):834\u2013839","journal-title":"J Urol"},{"issue":"5","key":"3666_CR25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N et al (2020) Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 203(5):902\u2013909","journal-title":"J Urol"},{"issue":"4","key":"3666_CR26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","volume":"3","author":"N Milbar","year":"2017","unstructured":"Milbar N, Kates M, Meera R et al (2017) Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer 3(4):293\u2013303","journal-title":"Bladder Cancer"},{"issue":"2","key":"3666_CR27","doi-asserted-by":"crossref","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A, Kates M (2020) An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer. Urol Oncol 38(2):40.e17-40.e24","journal-title":"Urol Oncol"},{"key":"3666_CR28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical Bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"issue":"4","key":"3666_CR29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28(4):543\u2013548","journal-title":"J Clin Oncol"},{"key":"3666_CR30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M et al (2016) Results of a randomized controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette\u2013Gu\u00e9rin for adjuvant treatment of patients with intermediate-and high-risk non\u2013muscle invasive bladder cancer. Eur Urol 69:1046\u20131052","journal-title":"Eur Urol"},{"issue":"1","key":"3666_CR31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette\u2013Gu\u00e9rin or Institutional Standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette\u2013Gu\u00e9rin Therapy (HYMN): a phase III, open-label randomised controlled trial. Eur Urol 75(1):63\u201371","journal-title":"Eur Urol"},{"issue":"4","key":"3666_CR32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","volume":"4","author":"J de Jong","year":"2018","unstructured":"de Jong J, Hendricksen K, Rosier M, Mostafid H, Boormans JL (2018) Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer 4(4):395\u2013401","journal-title":"Bladder Cancer"},{"issue":"1","key":"3666_CR33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.purol.2019.11.001","volume":"30","author":"T Marquette","year":"2020","unstructured":"Marquette T, Walz J, Rybikowski S (2020) Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG unresponsive non-muscle invasive bladder cancer patients. Prog Urol 30(1):35\u201340","journal-title":"Prog Urol"},{"key":"3666_CR34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777\u2013782","journal-title":"J Urol"},{"issue":"1","key":"3666_CR35","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M et al (2018) ElectroMotive Drug Administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG Failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 18(1):1224","journal-title":"BMC Cancer"},{"key":"3666_CR36","first-page":"149","volume":"103","author":"DJ Robins","year":"2017","unstructured":"Robins DJ, Sui W, Matulay JT et al (2017) Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin therapy. Clin Trial Urol 103:149\u2013153","journal-title":"Clin Trial Urol"},{"key":"3666_CR37","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CP Dinney","year":"2013","unstructured":"Dinney CP, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after Bacillus Calmette\u2013Gu\u00e9rin. Urol Oncol 31:1635\u20131642","journal-title":"Urol Oncol"},{"key":"3666_CR38","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41598-019-40145-0","volume":"9","author":"A Copland","year":"2019","unstructured":"Copland A, Sparrow A, Hart P, Diogo GR, Paul M, Azuma M, Reljic R (2019) Bacillus Calmette\u2013Gu\u00e9rin induces PD-L1 expression on antigen-presenting cells via autocrine and paracrine interleukin-STAT3 circuits. Sci Rep 9:3655","journal-title":"Sci Rep"},{"issue":"75","key":"3666_CR39","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"9","author":"A Hashizume","year":"2018","unstructured":"Hashizume A, Umemoto S, Yokose T, Nakamura Y, Yoshihara M, Shoji K, Wada S, Miyagi Y, Kishida T, Sasada T (2018) Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette\u2013Guerin. Oncotarget 9(75):34066\u201334078","journal-title":"Oncotarget"},{"issue":"6","key":"3666_CR40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/JU.0000000000000297","volume":"202","author":"MV Meng","year":"2019","unstructured":"Meng MV, Gschwend JE, Shore N et al (2019) Emerging immunotherapy options for Bacillus Calmette\u2013Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer. J Urol 202(6):1111\u20131119","journal-title":"J Urol"},{"issue":"6_suppl","key":"3666_CR41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2020.38.6_suppl.537","volume":"38","author":"A Rajkumar","year":"2020","unstructured":"Rajkumar A, Wang J, Neuzil KE, Kirschner AN, Chang SS (2020) Intravesical anti-PD-1 immune checkpoint inhibition in urothelial bladder cancer in a mouse model. J Clin Oncol 38(6_suppl):537\u2013537","journal-title":"J Clin Oncol"},{"issue":"15","key":"3666_CR42","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1200\/JCO.2020.38.15_suppl.5041","volume":"38","author":"AV Balar","year":"2020","unstructured":"Balar AV, Kamat AM, Kulkarni GS et al (2020) Pembrolizumab for the treatment of patients with Bacillus Calmette\u2013Gu\u00e9rin (BCG) unresponsive, high-risk (HR) non\u2013muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. J Clin Oncol 38(15):5041\u20135041. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5041","journal-title":"J Clin Oncol"},{"key":"3666_CR43","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/home. Accessed 30 Jan 2021"},{"issue":"5","key":"3666_CR44","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","volume":"188","author":"M Kowalski","year":"2012","unstructured":"Kowalski M, Guindon J, Brazas L et al (2012) A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with Bacillus Calmette\u2013Gu\u00e9rin. J Urol 188(5):1712\u20131718","journal-title":"J Urol"},{"issue":"4S, Supplement","key":"3666_CR45","first-page":"PD03-02 e72","volume":"203","author":"N Shore","year":"2020","unstructured":"Shore N, Beach M, O\u2019Donnell M et al (2020) Phase 3 results of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer. J Urol 203(4S, Supplement):PD03-02 e72","journal-title":"J Urol"},{"key":"3666_CR46","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","volume":"23","author":"N Navai","year":"2016","unstructured":"Navai N, Benedict W, Zhang G et al (2016) Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon \u03b12b formulated in Syn3 for BCG failures in non-muscle invasive bladder cancer. Ann Surg Oncol 23:4110\u20134114","journal-title":"Ann Surg Oncol"},{"key":"3666_CR47","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","volume":"35","author":"ND Shore","year":"2017","unstructured":"Shore ND, Boorjian SA, Canter DJ et al (2017) Intravesical rAd\u2013IFNa\/Syn3 for patients with high-grade, Bacillus Calmette\u2013Guerin\u2014refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol 35:3410\u20133416","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"3666_CR48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2020.38.6_suppl.442","volume":"38","author":"SA Boorjian","year":"2020","unstructured":"Boorjian SA, Dinney CPN (2020) Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial. J Clin Oncol 38(6_suppl):442\u2013442","journal-title":"J Clin Oncol"},{"issue":"Supplement 4","key":"3666_CR49","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1097\/01.JU.0000557578.25553.2c","volume":"201","author":"VT Packiam","year":"2019","unstructured":"Packiam VT, Barocas DA, Chamie K et al (2019) CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): 18 month follow-up from a multicenter phase II trial. J Urol 201(Supplement 4):e617","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03666-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:50:35Z","timestamp":1744185035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03666-w","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"26 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jacques Irani: Investigator in study NCT03519256 (evaluating Nivolumab\u2009+\u2014BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib); C\u00e9dric Lebacle: Investigator in study NCT03519256 (evaluating Nivolumab\u2009+\u2014BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib); Yohann Loriot: Investigator in study NCT03519256 (evaluating Nivolumab\u2009+\u2014BMS-986205), Investigator in study NCT04172675 (evaluating Erdafitinib).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}